Recurrent Liposarcoma

specific

The reemergence of liposarcoma after a period of remission.

Centers

Active Trials

—

Cancer Funding

Top Centers for Recurrent Liposarcoma(22)

Ranked by research excellence score (trials · grants · publications). Methodology →

#	Center	Research Tier	Active Trials	Cancer Funding	Score
1	Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive High-Volume Research Center	High-Volume Research Center	1	—	73.8
2	Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive		—	—	51.2
3	Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive		—	—	51.2
4	The University of Chicago Medicine Comprehensive Cancer CenterChicago, IL NCI Comprehensive		—	—	51.2
5	Masonic Cancer CenterMinneapolis, MN NCI Comprehensive		—	—	51.2
6	University of Colorado Cancer CenterAurora, CO NCI Comprehensive		—	—	51.2
7	Huntsman Cancer Institute at the University of UtahSalt Lake City, UT NCI Comprehensive		—	—	51.2
8	University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive		—	—	51.2
9	Sylvester Comprehensive Cancer CenterMiami, FL NCI Clinical		—	—	51.2
10	The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive		—	—	51.2
11	Medical College of Wisconsin Cancer CenterMilwaukee, WI		—	—	51.2
12	Holden Comprehensive Cancer CenterIowa City, IA NCI Comprehensive		—	—	51.2
13	Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical		—	—	51.2
14	The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive		—	—	51.2
15	University of Illinois Cancer CenterChicago, IL		—	—	51.2
16	University of Hawai‘i Cancer CenterHonolulu, HI NCI Clinical		—	—	51.2
17	Boston University Cancer CenterBoston, MA		—	—	51.2
18	Cancer Center at IllinoisUrbana, IL		—	—	51.2
19	University of Cincinnati Cancer CenterCincinnati, OH		—	—	51.2
20	Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL		—	—	51.2
21	Mayo Clinic Comprehensive Cancer Center, ArizonaScottsdale, AZ		—	—	51.2
22	The University of Vermont Cancer CenterBurlington, VT		—	—	51.2

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →